ALDX Q3 2024 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$318M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$15M

EPS (Diluted)

$-0.25

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$117M

Total Liabilities

$32M

Stockholders' Equity

$85M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$16M	-$10M	-69.0%
Net Income	-$15M	-$8M	-84.6%